Bleeding: Number of days on which a significant bleeding event occurred3 · People with a haematological disorder
Prophylactic platelet transfusion showed no clear difference in bleeding: Number of days on which a significant bleeding event… compared with non prophylactic or therapeutic platelet transfusion (low certainty).
1 finding from 1 review
Mortality: secondary to bleeding · People with a haematological disorder
Prophylactic platelet transfusion showed no clear difference in mortality: Secondary to bleeding compared with non prophylactic or therapeutic platelet transfusion (low certainty).
1 finding from 1 review
Number of platelet transfusions per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review
Bleeding: Numbers of patients with at least one significant bleeding event · People with a haematological disorder
Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in bleeding: Numbers of patients with at least one significant bleeding… compared with higher transfusion threshold (20,000 or 30,000) (moderate certainty).
1 finding from 1 review
Mortality: secondary to bleeding · People with a haematological disorder
Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in mortality: secondary to bleeding compared with higher transfusion threshold (20,000 or 30,000) (low certainty).
1 finding from 1 review
Intervention not reported
Overall survival · Adult patients with follicular lymphoma
The intervention showed no clear difference in overall survival (moderate certainty).
1 finding from 1 review
Intervention not reported
Treatment‐related mortality · Adult patients with follicular lymphoma
The intervention showed no clear difference in treatment‐related mortality (moderate certainty).
1 finding from 1 review
Intervention not reported
Progression‐free survival · Adult patients with follicular lymphoma
The intervention probably leads to lower progression‐free survival (moderate certainty).
1 finding from 1 review
Intervention not reported
Secondary malignancies AML/MDS · Adult patients with follicular lymphoma
The intervention showed no clear difference in secondary malignancies AML/MDS (low certainty).
1 finding from 1 review
Intervention not reported
Secondary malignancies Solid cancer · Adult patients with follicular lymphoma
The intervention showed no clear difference in secondary malignancies Solid cancer (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events · Adult patients with follicular lymphoma
1 finding from 1 review
Mortality Median · patients with primary CNS lymphoma
Cytarabine plus high‐dose methotrexate showed no clear difference in mortality (median 3 years) compared with high‐dose methotrexate alone (moderate certainty).
1 finding from 1 review
Progression/relapse · patients with primary CNS lymphoma
Cytarabine plus high‐dose methotrexate probably leads to lower progression/relapse (median 3 years) compared with high‐dose methotrexate alone (moderate certainty).
1 finding from 1 review
Treatment‐related mortality · patients with primary CNS lymphoma
Cytarabine plus high‐dose methotrexate showed no clear difference in treatment‐related mortality compared with high‐dose methotrexate alone (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with primary CNS lymphoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe adverse effects (grade 3+): Infection · patients with primary CNS lymphoma
Cytarabine plus high‐dose methotrexate probably leads to higher infections (grade 3 to 4) compared with high‐dose methotrexate alone (moderate certainty).
1 finding from 1 review